"Perfect Heartio" Drink and Cardiovascular Health
Beneficial Effects of "Perfect Heartio" Drink in Improving Cardiovascular Health
1 other identifier
interventional
55
1 country
1
Brief Summary
Noncommunicable diseases (NCDs) such as type 2 diabetes (T2D) and cardiovascular disease (CVD) account for more deaths globally than any other condition. In 2018, the WHO reported that NCDs accounted for 71% of global deaths. They also showed that low- and middle-income countries are disproportionately affected by NCDs, accounting for 85% of NCD-related deaths among individuals aged 30-69 y. Among NCDs, CVD is the leading and fourth-leading causes of death, accounting for 19.5 million deaths worldwide in 2018. Furthermore, despite increasing global awareness, the prevalence of these conditions continues to increase at alarming rates. Deaths from CVD are expected to reach 23.6 million annually by 2030 from 17.6 million deaths in 2016. The underlying aetiology of these conditions is complex, as they can be influenced by several environmental, genetic, and behavioural factors. However, diet and nutrition play a particularly important role in these conditions, especially in the context of the double burden of malnutrition facing many low- and middle-income countries.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable cardiovascular-diseases
Started Apr 2025
Shorter than P25 for not_applicable cardiovascular-diseases
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2025
CompletedFirst Submitted
Initial submission to the registry
June 24, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2025
CompletedFirst Posted
Study publicly available on registry
July 2, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2025
CompletedJuly 8, 2025
July 1, 2025
3 months
June 24, 2025
July 2, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Lipid profile
Total cholesterol levels, Triglycerides levels, LDL- cholesterol levels, HDL-cholesterol levels
Week 0, 4, 8 and 12
Cardiac inflammatory levels
C-reactive protein
Week 0, 4, 8 and 12
Cardiac injury levels
Creatine kinase
Week 0, 4, 8 and 12
Cardiac remodelling status
Matrix metalloproteinases-9 (MMP-9)
Week 0, 4, 8 and 12
Secondary Outcomes (2)
Quality of Life of subject
Week 0, 4, 8 and 12
Self-perceived health status
Week 0, 4, 8 and 12
Study Arms (1)
Perfect Heartion Drink Interventional Arm
EXPERIMENTALSubjects will be required to consume PH drink for 12 weeks, at the dosage of 15g twice daily. Compliance form will be given to monitor the compliance of subject.
Interventions
Perfect Heartio (PH) drink is a nutritional drink composed of diluted herbal extracts of TCM, including ginger, Glycyrrhiza uralensis, Alternanthera sessilis, Panax notoginseng, Red date, Codonopsis pilosula, Ligusticum chuanxiong, Astragalus membranaceus.
Eligibility Criteria
You may qualify if:
- General healthy subjects during enrolment
- Age 18 and above
- Willing to comply with interventional plan and comes to do follow up
- Willing to gives consent
You may not qualify if:
- Use nonsteroidal anti-inflammatory drugs (NSAIDs) more than once a week during enrolment
- Use of anticoagulants or corticosteroids
- Use of individual supplements of vitamin A, E, or beta carotene more than once a week during enrolment
- Renal failure or dialysis, cirrhosis, other serious conditions that precluded participation
- No previous history of cancer (except nonmelanoma skin cancer)
- Pregnant or lactating woman
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- The Perfect Series Sdn Bhdlead
- UCSI Universitycollaborator
Study Sites (1)
UCSI University
Cheras, Kuala Lumpur, 56000, Malaysia
Related Publications (2)
Cooper F. How to publish a winning newsletter. Health Care Can. 1979 Sep;21(9):41-2. No abstract available.
PMID: 10243891BACKGROUNDLing Lee W, Chinna K, Sumintono B. Psychometrics assessment of HeartQoL questionnaire: A Rasch analysis. Eur J Prev Cardiol. 2021 Oct 13;28(12):e1-e5. doi: 10.1177/2047487320902322. Epub 2020 Feb 4. No abstract available.
PMID: 34647582BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Chung Keat Tan, PhD
UCSI University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 24, 2025
First Posted
July 2, 2025
Study Start
April 1, 2025
Primary Completion
June 30, 2025
Study Completion
December 31, 2025
Last Updated
July 8, 2025
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
- Time Frame
- Upon publication of the study outcomes, for a time frame of 5 years
- Access Criteria
- The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. All of the individual participant data collected during the trial, after de-identification will be shared upon reasonable request. Additional documents including study protocol, statistical analysis plan, informed consent form and clinical study report will also be made available. The data will be available immediately following publication with no end date. Data will be shared with anyone who wishes to access with reasonable request. The data can be used for any types of analyses.
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. All of the individual participant data collected during the trial, after de-identification will be shared upon reasonable request. Additional documents including study protocol, statistical analysis plan, informed consent form and clinical study report will also be made available. The data will be available immediately following publication with no end date. Data will be shared with anyone who wishes to access with reasonable request. The data can be used for any types of analyses.